ARIXTRA indications for the prophylaxis of venous thromboembolism (VTE) after abdominal surgery in high-risk patients*
ARIXTRA helped protect most patients from venous thromboembolism (VTE) following abdominal surgery. [12]
*Surgery was high risk if patients were >60 years of age, or >40 and <60 with 1 or more additional risk factors for VTE or who were undergoing abdominal surgery with general anesthesia expected to last >45 minutes. [12]
ARIXTRA was well tolerated [12]
97.2% of patients who received ARIXTRA following abdominal surgery were free from major bleeding when the dose was administered 6 hours after surgery. [12]
†Major bleeding was defined as fatal bleeding, bleeding that was retroperitoneal, intracranial, intraspinal, or involved in any other critical organ, bleeding leading to reoperation or intervention, or a BI >2.0. BI=number of units of transfused packed RBC or whole blood + difference between prebleeding and postbleeding hemoglobin in g/dL.
Study summary for VTE prophylaxis after abdominal surgery [12,13]
PEGASUS was a randomized, double-blind, double-dummy trial of abdominal surgery patients at risk for thromboembolic complications. Patients received ARIXTRA 2.5 mg once-daily or dalteparin 5,000 IU SC once-daily, with one 2,500 IU SC preoperative injection and one 2,500 IU SC first postoperative injection.